Neuroendocrine Tumors Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment

DelveInsight's analysis of the Neuroendocrine Tumors pipeline reveals 70+ key companies working on 75+ therapies

Published on Feb. 16, 2026

Got story updates? Submit your updates here. ›

DelveInsight's assessment shows the Neuroendocrine Tumors pipeline constitutes 70+ key companies continuously working towards developing 75+ Neuroendocrine Tumors treatment therapies, including analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments.

Why it matters

The Neuroendocrine Tumors pipeline report provides comprehensive insights into the present clinical development scenario and growth prospects across the Neuroendocrine Tumors market. The report highlights the emerging therapies that are expected to have a significant impact on the Neuroendocrine Tumors market in the coming years.

The details

The Neuroendocrine Tumors Pipeline report covers around 75+ products under different phases of clinical development, including late-stage products (Phase III), mid-stage products (Phase II), early-stage products (Phase I), pre-clinical and discovery stage candidates, and discontinued & inactive candidates. The report also provides details on the Route of Administration, Molecule Type, and the key companies involved in Neuroendocrine Tumors drug development.

  • In October 2025, Belzutifan (Welireg) demonstrated durable responses in patients with advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm Phase II trial.
  • In March 2025, the FDA approved CABOMETYX® (cabozantinib) for two new indications related to neuroendocrine tumors.
  • In February 2025, ITM Isotope Technologies Munich SE revealed encouraging topline findings from its Phase III COMPETE study assessing ITM-11 (n.c.a. 177Lu-edotreotide).
  • In January 2025, Cabozantinib (Cabometyx) demonstrated a significant improvement in progression-free survival (PFS) compared to placebo in patients with extrapancreatic neuroendocrine tumors (NETs) in the Phase 3 CABINET trial.

The players

Advanced Accelerator Applications (AAA)/Novartis

An American autonomous driving company and is a subsidiary of Alphabet Inc., Google's parent company.

Ipsen Biopharmaceuticals

A prominent radiopharmaceutical biotechnology firm.

Novartis

A global pharmaceutical company.

Pfizer

A multinational pharmaceutical corporation.

Bausch Health and Ono Pharma

A specialty pharmaceutical company.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.